---
title: "Kesimpta (ofatumumab) in relapsing multiple sclerosis: Access and coverage questions"
description: "Access and coverage questions on Kesimpta (ofatumumab) in relapsing multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Patient support, Access and billing, Cost and coverage, Prior authorization, and Access support. Questions: What injection training does Novartis offer for Kesimpta patients? What are the NDC numbers for Kesimpta? Is there a Kesimpta copay card (Access Card Program)? How much do commercially insured patients pay for Kesimpta with the copay program? 11 further questions follow. 15 questions quoted from 6 sources."
canonical: "https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/access-and-coverage"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kesimpta (ofatumumab) in relapsing multiple sclerosis: Access and coverage questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kesimpta](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf)

## Patient support

<a id="kesimpta-injection-training"></a>

### What injection training does Novartis offer for Kesimpta patients?

> “Alongside KESIMPTA offers supplemental resources and flexible assistance to patients on how to administer KESIMPTA—fitting into their needs via:
>
> Quick Tips for Use brochure (sent to patient's home with Welcome Package)
>
> On-demand training videos at KESIMPTA.com
>
> Virtual injection training (eg, video chat) by nurses”

Source: [KESIMPTA: FAQs, captured 2026-11-13](https://www.kesimptahcp.com/resources/faqs#:~:text=Alongside%20KESIMPTA%20offers%20supplemental%20resources,%28eg%2C%20video%20chat%29%20by%20nurses)

On the page, select: What injection training support does Novartis offer?

> “Demonstrate KESIMPTA administration using the Sensoready<sup>®</sup> Demo Pen. Demo pens and videos are provided by Novartis (including supplemental one-on-one virtual training for patients)<sup>1</sup>”

Source: [KESIMPTA: Starting Patients on KESIMPTA® (ofatumumab) | HCP, captured 2026-11-13](https://www.kesimptahcp.com/starting-patients/getting-started#:~:text=Demonstrate%20KESIMPTA%20administration%20using%20the,supplemental%20one%2Don%2Done%20virtual%20training%20for)

Note: Manufacturer materials use two names for KESIMPTA patient support: Alongside KESIMPTA (Authorization and Appeals Kit, kesimptahcp.com FAQ page) and Novartis Patient Support (kesimptahcp.com coverage and support page); the patient authorization form uses both.

<a id="kesimpta-patient-support-program"></a>

### What patient support does Novartis offer for Kesimpta?

> “Access Reimbursement Manager
>
> Helps navigate the prior authorization and appeals process 
> Troubleshoots any coverage or reimbursement issues”

Source: [KESIMPTA: Coverage and Support, captured 2026-11-13](https://www.kesimptahcp.com/starting-patients/coverage-support#:~:text=Access%20Reimbursement%20Manager,any%20coverage%20or%20reimbursement%20issues)

> “Patient Access Coordinator
>
> Completes benefits verification 
> Informs the patient of coverage status and next steps”

Source: [KESIMPTA: Coverage and Support, captured 2026-11-13](https://www.kesimptahcp.com/starting-patients/coverage-support#:~:text=Patient%20Access%20Coordinator,coverage%20status%20and%20next%20steps)

> “Dedicated Coordinator
>
> Provides resources for and performs supplemental injection training
> Provides 1-on-1 tailored support for up to 2 years”

Source: [KESIMPTA: Coverage and Support, captured 2026-11-13](https://www.kesimptahcp.com/starting-patients/coverage-support#:~:text=Dedicated%20Coordinator,for%20up%20to%202%20years)

> “Connect with a Coordinator at 1-855-KESIMPTA (1-855-537-4678).”

Source: [KESIMPTA: FA-11488397.PDF, page 2, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=2)

Note: Manufacturer materials use two names for KESIMPTA patient support: Alongside KESIMPTA (Authorization and Appeals Kit, kesimptahcp.com FAQ page) and Novartis Patient Support (kesimptahcp.com coverage and support page); the patient authorization form uses both.

## Access and billing

<a id="kesimpta-ndc"></a>

### What are the NDC numbers for Kesimpta?

> “KESIMPTA Sensoready Pen:  
> Carton of one 20 mg/0.4 mL single-dose prefilled Sensoready Pen 
>
> NDC 0078-1007-68  
> KESIMPTA Prefilled Syringe: 
> Carton of one 20 mg/0.4 mL single-dose prefilled syringe 
>
>
> NDC 0078-1007-69”

Source: [KESIMPTA: Prescribing information, page 12, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=12)

<a id="kesimpta-specialty-pharmacy"></a>

### How is Kesimpta dispensed (specialty pharmacy)?

> “If a prior authorization (PA) is not needed, or was needed and has been  
> approved, the prescription is sent directly to the patient’s preferred specialty  
> pharmacy to dispense (insurance mandates may apply).”

Source: [KESIMPTA: FA-11488397.PDF, page 9, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=9)

## Cost and coverage

<a id="kesimpta-copay-card"></a>

### Is there a Kesimpta copay card (Access Card Program)?

> “<sup>†</sup>Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance who are initially denied coverage may receive free KESIMPTA for up to 12 months while seeking coverage. Patients with commercial insurance who have coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at start.kesimpta.com.”

Source: [KESIMPTA: Coverage and Support, captured 2026-11-13](https://www.kesimptahcp.com/starting-patients/coverage-support#:~:text=apply.%20Offer%20not%20valid%20under,Terms%20%26%20Conditions%20at%20start.kesimpta.com.)

> “The Access Card Program  
> helps eligible commercially insured patients to*,†:
> • Pay as little as $0 co-pay until the annual limit  
> is reached
> • Receive free medication for up to 1 year while 
> pursuing coverage”

Source: [KESIMPTA: FA-11488397.PDF, page 9, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=9)

> “Co-pay Program Terms & Conditions: Limitations apply. Up to a $18,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal 
> or state program. Novartis reserves the right to rescind, revoke, or amend this Program without notice. See complete Terms & Conditions for details  
> at start.kesimpta.com.”

Source: [KESIMPTA: FA-11488397.PDF, page 9, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=9)

<a id="kesimpta-cost-commercial"></a>

### How much do commercially insured patients pay for Kesimpta with the copay program?

> “Eligible commercial patients prescribed KESIMPTA<sup>®</sup> (ofatumumab)  
> may pay $0 out of pocket. Visit start.kesimpta.com for Program  
> Terms and Conditions and more information.*”

Source: [KESIMPTA: FA-11488397.PDF, page 7, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=7)

> “Limitations apply. Up to a $18,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves  
> the right to rescind, revoke, or amend this Program without notice. See complete Terms & Conditions for details at start.kesimpta.com.”

Source: [KESIMPTA: FA-11488397.PDF, page 7, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=7)

<a id="kesimpta-copay-program-exclusions"></a>

### Who is not eligible for the Kesimpta copay program?

> “Co-pay Program: Limitations apply. Valid only for those with private insurance. The Program includes the $0 Access Cardand Rebate, with a combined annual limit of $18,000. Patient is responsible for any costs once 
> limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where 
> the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient’s insurance.”

Source: [KESIMPTA: FA-11400292.PDF, page 2, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11400292-ksm-hcp-pss-patient-authorization-form-update-digital-4-25/FA-11400292.PDF#page=2)

<a id="kesimpta-bridge-program"></a>

### Can patients get free Kesimpta while insurance coverage is denied (Bridge Program)?

> “Bridge Program: Must have commercial insurance, a valid prescription for KESIMPTA, and a denial of insurance coverage based on a prior authorization requirement to qualify. Eligible patients may 
> receive a monthly maintenance dose for up to 12 months or until insurance coverage approval, whichever occurs first. Not available to patients whose medications are reimbursed in whole or in part by 
> Medicare, Medicaid, TRICARE, VA, DoD or any other federal or state program, or where prohibited by law. No purchase necessary. Program is not health insurance, nor is participation a guarantee of 
> insurance coverage. Other limitations may apply. Novartis reserves the right to rescind, revoke or amend this Program without notice.”

Source: [KESIMPTA: FA-11400292.PDF, page 2, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11400292-ksm-hcp-pss-patient-authorization-form-update-digital-4-25/FA-11400292.PDF#page=2)

> “*If a PA is not started within 9 months, patients will lose eligibility for the Bridge Program.”

Source: [KESIMPTA: FA-11488397.PDF, page 10, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=10)

<a id="kesimpta-medicare"></a>

### Does the Kesimpta copay card work with Medicare or Medicaid?

> “Limitations apply. See program terms and conditions on back of card. This offer is not valid for 
> cash-paying patients, Medicare, Medicaid, or any other federal or state program.”

Source: [KESIMPTA: FA-11488397.PDF, page 9, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=9)

> “Government-insured patients are not eligible for the Access Card Program, but may  
> qualify for the Novartis Patient Assistance Foundation (NPAF).<sup>‡</sup>”

Source: [KESIMPTA: FA-11488397.PDF, page 9, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=9)

<a id="kesimpta-patient-assistance"></a>

### Is there a Kesimpta patient assistance program for uninsured patients?

> “Novartis Patient Assistance Foundation, Inc., (NPAF) provides free KESIMPTAto eligible uninsured and underinsured 
> patients. Proof of income is required.”

Source: [KESIMPTA: FA-11400292.PDF, page 1, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11400292-ksm-hcp-pss-patient-authorization-form-update-digital-4-25/FA-11400292.PDF#page=1)

> “The NPAF is an independent  
> foundation that offers free Novartis medication to patients who are experiencing financial  
> hardship and have limited or no prescription coverage 
> For more information, patients can visit PAP.Novartis.com.”

Source: [KESIMPTA: FA-11488397.PDF, page 9, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=9)

> “If patients cannot afford their medication, or are uninsured, they are referred to the NPAF,  
> which provides free medication to eligible uninsured or underinsured patients<sup>‡</sup>”

Source: [KESIMPTA: FA-11488397.PDF, page 9, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=9)

> “Patients must be a US resident and meet specific income requirements. Patients also must have limited or no private or public prescription coverage. 
> Visit PAP.Novartis.com for additional details.”

Source: [KESIMPTA: FA-11488397.PDF, page 9, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=9)

## Prior authorization

<a id="kesimpta-prior-authorization"></a>

### Does Kesimpta need prior authorization?

> “Every health plan manages access to KESIMPTA<sup>®</sup> (ofatumumab) differently. Even if the decision 
> to prescribe KESIMPTA to patients with RMS is the right decision clinically, you may run into 
> restrictions put in place by a health plan, such as PAs, step edits, or no coverage at all.”

Source: [KESIMPTA: FA-11488397.PDF, page 3, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=3)

> “For plans requiring a PA request for KESIMPTA: 
> • Complete a PA request using the health plan's PA form
> • If a PA is denied, submit a Letter of Appeal (see pages 15 and 16  
> for sample letters)”

Source: [KESIMPTA: FA-11488397.PDF, page 12, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=12)

> “Submitting a PA may be completed directly through the insurer  
> or by using Alongside KESIMPTA or CoverMyMeds<sup>®</sup>.”

Source: [KESIMPTA: FA-11488397.PDF, page 12, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=12)

Note: Manufacturer materials use two names for KESIMPTA patient support: Alongside KESIMPTA (Authorization and Appeals Kit, kesimptahcp.com FAQ page) and Novartis Patient Support (kesimptahcp.com coverage and support page); the patient authorization form uses both.

<a id="kesimpta-prior-authorization-criteria"></a>

### What do health plans require for Kesimpta prior authorization?

> “Each plan may have additional PA requirements for RMS, which may include 1 or more of the  
> following, if applicable:”

Source: [KESIMPTA: FA-11488397.PDF, page 12, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=12)

> “History of at least 1 treatment failure (including 
> any DMTs). Failure may be defined as:
>
> •  New evidence of disease activity  
> (eg, relapse or new MRI lesions) or  
> evidence of increased disability
>
> •  Continued worsening of symptoms
> □  One clinical relapse during the prior year  
> (eg, functional disability, hospitalization, and  
> acute steroid therapy)
> □  A single clinical demyelinating event and 2 or  
> more brain lesions 
> □  A brain MRI scan demonstrating at least 1 Gd+ 
> lesion within the past 6 months”

Source: [KESIMPTA: FA-11488397.PDF, page 12, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=12)

> “Checklist for a complete PA submission 
> □  Patient's name, date of birth, insurance ID number, insurance group  
> number, and dates of service
> □  Patient’s diagnosis and corresponding ICD-10 code(s)
> □  List of previous therapies”

Source: [KESIMPTA: FA-11488397.PDF, page 12, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=12)

<a id="kesimpta-appeal-denial"></a>

### How do you appeal a Kesimpta insurance denial?

> “Letter of Appeal 
> If a plan has PA criteria and denies your PA request, submit a Letter of Appeal. 
> Letter of Medical Necessity 
> If KESIMPTA is not on formulary or NDC blocked, submit a Letter of Medical Necessity. 
> If the Letter of Medical Necessity is denied, submit a Letter of Appeal.”

Source: [KESIMPTA: FA-11488397.PDF, page 3, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=3)

> “Keep in mind there can be multiple levels of appeal, and you should refer  
> to the health plan's specific appeal guidelines. Many health plans will  
> accept up to 3 levels of appeal of PA denials. The third level of appeal  
> may include a review by an independent, non–insurance-affiliated  
> external review board or hearing. Submitting an appeal may be completed  
> on your own or by using Alongside KESIMPTA or CoverMyMeds<sup>®</sup>.”

Source: [KESIMPTA: FA-11488397.PDF, page 14, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=14)

Note: Manufacturer materials use two names for KESIMPTA patient support: Alongside KESIMPTA (Authorization and Appeals Kit, kesimptahcp.com FAQ page) and Novartis Patient Support (kesimptahcp.com coverage and support page); the patient authorization form uses both.

## Access support

<a id="kesimpta-start-form"></a>

### How do you start a patient on Kesimpta (Start Form)?

> “Submit 1-page Start Form and see additional helpful resources to help support you and your staff in starting patients”

Source: [KESIMPTA: Starting Patients on KESIMPTA® (ofatumumab) | HCP, captured 2026-11-13](https://www.kesimptahcp.com/starting-patients/getting-started#:~:text=Submit%201%2Dpage%20Start%20Form%20and,your%20staff%20in%20starting%20patients)

> “Submit the SF through 
> CoverMyMeds.com or 
> via fax to 1-833-318-0680”

Source: [KESIMPTA: FA-11488397.PDF, page 8, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=8)

> “REMINDER: You and your patient must sign the SF prior to 
> submitting to Alongside KESIMPTA. Incomplete SFs can cause 
> a delay in the support process.”

Source: [KESIMPTA: FA-11488397.PDF, page 8, captured 2026-11-13](https://www.cdn.fuse.novartis.com/fa-11488397-ksm-omb-authorization-and-appeals-kit-digital-label-update-8-25_v2.2_clean_1/FA-11488397.PDF#page=8)

Note: Manufacturer materials use two names for KESIMPTA patient support: Alongside KESIMPTA (Authorization and Appeals Kit, kesimptahcp.com FAQ page) and Novartis Patient Support (kesimptahcp.com coverage and support page); the patient authorization form uses both.

<a id="kesimpta-samples"></a>

### Can patients start Kesimpta with samples?

> “*Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA and is intended to give patients a chance to see if KESIMPTA may be right for them. Contact your Sales Representative to learn more.”

Source: [KESIMPTA: Starting Patients on KESIMPTA® (ofatumumab) | HCP, captured 2026-11-13](https://www.kesimptahcp.com/starting-patients/getting-started#:~:text=%2ASample%20program%20is%20only%20available,Sales%20Representative%20to%20learn%20more.)

## Related pages
- [Medical information: Kesimpta (ofatumumab): Relapsing multiple sclerosis](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/storage-and-supply)
